An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.
Source summary generated November 6, 2026; this date does not indicate completed review.
Quotes from three independent practitioners, with their sources. Research context only.
What it is and how it works
From the published literature on Gonadorelin; the papers are listed at the end. Research summary, not a recommendation.
What it is
Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH, also called LHRH), a natural decapeptide of 10 amino acids made by a small group of nerve cells in the hypothalamus. Its structure was worked out in 1971 by the groups of Andrew Schally and Roger Guillemin, who shared the 1977 Nobel Prize for the discovery. Gonadorelin has the same sequence as the natural hormone, which distinguishes it from the modified long-acting GnRH analogues (leuprolide, triptorelin and others) used to suppress sex hormones. It has been an FDA-approved product for diagnostic testing of pituitary function (Factrel) and, as a pump-delivered form (Lutrepulse), for inducing ovulation; both human products were later withdrawn from the US market for commercial reasons, and gonadorelin remains an approved veterinary drug for cattle. In the United States it is now obtained from compounding pharmacies.
How it works
GnRH is released from the hypothalamus in pulses, roughly every one to two hours, and travels through a short portal blood system to the pituitary, where it binds the GnRH receptor on gonadotroph cells. Each pulse triggers release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which act on the testes to drive testosterone production and sperm formation and on the ovaries to drive follicle growth, estrogen production and ovulation. The pattern matters more than the amount: pulsed GnRH stimulates the axis, whereas continuous exposure desensitizes the receptor and shuts LH and FSH off, which is how the long-acting analogues suppress sex hormones. Gonadorelin is cleared from the blood within minutes, so for stimulation it is given as a single diagnostic injection or by a programmable pump that mimics the natural pulses.
What it has been studied for
Diagnostic testing of pituitary gonadotropin reserve (the original clinical studies)
Ovulation induction by pulsatile GnRH in women with hypothalamic amenorrhea and polycystic ovary syndrome (Cochrane review and controlled studies)
Induction of puberty, testosterone production and sperm formation in men with congenital hypogonadotropic hypogonadism (comparative human studies)
Men who did not respond to gonadotropin injections (human case series)
Physiology of the GnRH neuron and pulse generator (reviews)
Strength of the evidence
Approved drugGonadorelin has held FDA approval for diagnostic testing and for pulsatile ovulation induction, and pulsatile GnRH is an established treatment for hypogonadotropic hypogonadism in the endocrine literature; the human products are no longer marketed in the United States, and its popular use alongside testosterone therapy to maintain testicular function has not been tested in a published controlled trial.
What the literature reports on safety
In the diagnostic and pump studies gonadorelin was reported as well tolerated, with injection-site reactions, headache, flushing and nausea the most common effects and rare allergic reactions including anaphylaxis described in the labels. Pulsatile use in women carries a risk of multiple pregnancy and, less often than with gonadotropin injections, ovarian hyperstimulation. The approved human products (Factrel and Lutrepulse) were discontinued in the United States, so current use relies on compounded gonadorelin; it is prohibited in sport by the World Anti-Doping Agency for male athletes as a hormone that raises testosterone.
Review · Bayram N, van Wely M, et al. · Cochrane Database of Systematic Reviews (2004) · PMID 14973957
A Cochrane review that found pulsatile GnRH induced ovulation in women with polycystic ovary syndrome but that the randomized evidence on pregnancy rates was too small to draw firm conclusions.
Cohort study · Zhang L, Cai K, et al. · American Journal of Men's Health (2019) · PMID 30569789
In men with congenital GnRH deficiency a pulsatile gonadorelin pump produced sperm in the ejaculate sooner than gonadotropin injections, with similar eventual success.
Lab (in vitro) · Matsuo H, Baba Y, et al. · Biochemical and Biophysical Research Communications (1971) · PMID 4936338
Reported the 10-amino-acid sequence of GnRH, which is the sequence of gonadorelin.
Sources checked: PubMed/PMC (E-utilities esummary on every PMID), written 2026-11-06.
Hunter Williams, in his own words
Figures quoted, not recommended. These are Hunter Williams' descriptions, not an agreed treatment protocol.
5 quotations from his library pages, each with its source. A quote marked with a product name is about a blend that includes Gonadorelin.
What he says it is for
“The only real use case I see is older men on TRT who are done having children and just want to prevent extreme testicular shrinkage on a budget. For fertility goals, it's not the move.”
“Typical dose is around 100 mcg daily injections. The half-life is short, only minutes in circulation, so you'd really want to dose two or three times a day for full effect.”
Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.
What have the teachers said about Gonadorelin? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.
AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.
All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.